NovaBay Pharmaceuticals Inc (NBY)
0.78
+0.03
(+4.00%)
USD |
NYAM |
Nov 04, 16:00
0.78
0.00 (0.00%)
After-Hours: 20:00
NovaBay Pharmaceuticals Research and Development Expense (TTM): 0.043M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.043M |
| March 31, 2024 | 0.056M |
| December 31, 2023 | 0.047M |
| September 30, 2023 | 0.109M |
| June 30, 2023 | 0.139M |
| March 31, 2023 | 0.157M |
| December 31, 2022 | 0.175M |
| September 30, 2022 | 0.117M |
| June 30, 2022 | 0.086M |
| March 31, 2022 | 0.067M |
| December 31, 2021 | 0.044M |
| September 30, 2021 | 0.072M |
| June 30, 2021 | 0.187M |
| March 31, 2021 | 0.281M |
| December 31, 2020 | 0.285M |
| September 30, 2020 | 0.267M |
| June 30, 2020 | 0.191M |
| March 31, 2020 | 0.108M |
| December 31, 2019 | 0.184M |
| September 30, 2019 | 0.273M |
| June 30, 2019 | 0.269M |
| March 31, 2019 | 0.298M |
| December 31, 2018 | 0.259M |
| September 30, 2018 | 0.298M |
| June 30, 2018 | 0.385M |
| Date | Value |
|---|---|
| March 31, 2018 | 0.394M |
| December 31, 2017 | 0.41M |
| September 30, 2017 | 0.42M |
| June 30, 2017 | 0.292M |
| March 31, 2017 | 0.50M |
| December 31, 2016 | 1.371M |
| September 30, 2016 | 2.44M |
| June 30, 2016 | 3.999M |
| March 31, 2016 | 5.078M |
| December 31, 2015 | 5.728M |
| September 30, 2015 | 6.908M |
| June 30, 2015 | 7.657M |
| March 31, 2015 | 8.538M |
| December 31, 2014 | 9.483M |
| September 30, 2014 | 11.12M |
| June 30, 2014 | 11.32M |
| March 31, 2014 | 12.02M |
| December 31, 2013 | 12.41M |
| September 30, 2013 | 10.49M |
| June 30, 2013 | 10.50M |
| March 31, 2013 | 9.936M |
| December 31, 2012 | 9.275M |
| September 30, 2012 | 9.355M |
| June 30, 2012 | 8.864M |
| March 31, 2012 | 9.255M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
0.043M
Minimum
Jun 2024
0.285M
Maximum
Dec 2020
0.1376M
Average
0.117M
Median
Sep 2022
Research and Development Expense (TTM) Benchmarks
| Palatin Technologies Inc | 22.40M |
| iBio Inc | 5.185M |
| Theriva Biologics Inc | 14.61M |
| Oragenics Inc | 13.38M |
| Nanoviricides Inc | 5.437M |